Next Article in Journal
Percutaneous Mitral Valve Repair with the MitraClip System in the Current Clinical Practice
Previous Article in Journal
Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors
Open AccessFeature PaperReview

Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western Italy) Consensus Document

1
Department of Internal Medicine and Hypertension Division, University of Turin, “Città della Salute e della Scienza” Hospital, 10126 Turin, Italy
2
Cardio-oncology Unit, Humanitas Gradenigo Hospital, 10153 Turin, Italy
3
Internal Medicine Division, S. Andrea Hospital, 13100 Vercelli, Italy
4
Cardiology Department, Alliance Medical, 15100 Alessandria, Italy
5
Department of Cardiology, San Luigi Gonzaga Hospital, 10043 Turin, Italy
6
Cardiology Department, Maria Vittoria Hospital, 10144 Turin, Italy
7
Cardiology Department, Ivrea Hospital, 10015 Turin, Italy
8
Cardiology Consultant, Cottolengo Hospital, 10152 Turin, Italy
9
Division of Cardiology, Department of Cardiovascular and Thoracic, Città della Salute e della Scienza Hospital and University of Turin, 10126 Turin, Italy
10
Rete Oncologica Piemonte Valle d’Aosta Interregional Department, Città della Salute e Scienza Hospital, 10126 Turin, Italy
*
Author to whom correspondence should be addressed.
Received: 17 December 2020 / Revised: 6 January 2021 / Accepted: 12 January 2021 / Published: 15 January 2021
Cancer patients receiving a potentially cardiotoxic oncologic therapy have an increased risk of cardiovascular adverse events (CVAEs), especially in presence of concomitant arterial hypertension (AH). Therefore, cancer patients should be evaluated before, during and after cardiotoxic treatments, to early identify new-onset or worsening AH or CVAEs. An expert panel of oncology networks from Piedmont and Aosta Valley (North-Western Italy) aimed to provide recommendations to support health professionals in selecting the best management strategies for patients, considering the impact on outcome and the risk–benefit ratio of diagnostic/therapeutic tools. We proposed an useful document for evaluating and managing AH related to cancer treatments. Patients should be divided into 4 cardiovascular (CV) risk groups before starting potentially cardiotoxic therapies: patients with low/moderate risk who should be entirely evaluated by oncologists and patients with high/very high risk who should be referred to a cardiologist or arterial hypertension specialist. According to the CV risk class, every patient should be followed up during cancer treatment to monitor any possible CV complications. Adequate control of AH related to antineoplastic treatments is crucial to prevent severe CVAEs. In the presence of high-profile risk or lack of response to anti-hypertensive therapy, the patients should be managed with a cardiovascular-oncology expert center. View Full-Text
Keywords: cardio-oncology; arterial hypertension; cardiovascular adverse event; cardiovascular prevention; cardiotoxic treatments cardio-oncology; arterial hypertension; cardiovascular adverse event; cardiovascular prevention; cardiotoxic treatments
Show Figures

Graphical abstract

MDPI and ACS Style

Mingrone, G.; Coletti Moia, E.; Delsignore, E.; Demicheli, G.; Destefanis, P.; Forno, D.; Giglio Tos, G.; Luciano, A.; Pinna, G.; Ravera, L.; Fava, A.; Veglio, F.; Bertetto, O.; Milan, A. Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western Italy) Consensus Document. Hearts 2021, 2, 61-73. https://0-doi-org.brum.beds.ac.uk/10.3390/hearts2010006

AMA Style

Mingrone G, Coletti Moia E, Delsignore E, Demicheli G, Destefanis P, Forno D, Giglio Tos G, Luciano A, Pinna G, Ravera L, Fava A, Veglio F, Bertetto O, Milan A. Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western Italy) Consensus Document. Hearts. 2021; 2(1):61-73. https://0-doi-org.brum.beds.ac.uk/10.3390/hearts2010006

Chicago/Turabian Style

Mingrone, Giulia; Coletti Moia, Elena; Delsignore, Erica; Demicheli, Gloria; Destefanis, Paola; Forno, Davide; Giglio Tos, Giovanna; Luciano, Alessia; Pinna, Giuliano; Ravera, Laura; Fava, Antonella; Veglio, Franco; Bertetto, Oscar; Milan, Alberto. 2021. "Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western Italy) Consensus Document" Hearts 2, no. 1: 61-73. https://0-doi-org.brum.beds.ac.uk/10.3390/hearts2010006

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop